Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 1997

View Archived Issues

Tuberous sclerosis complex gene identified

Myotrophin NDA review period extended by FDA

Neoprobe announces additional trials with RIGScan CR49

NIH report on marijuana therapy released

SIBIA Neurosciences and Lilly near completion of VGCC research collaboration

Delsys, new drug manufacturing corporation, formed

InSite Vision exercises option to license glaucoma gene

More obstacles to Novopharm's launch of generic ranitidine

Xechem granted patent for paclitaxel isolation and purification method

Paclitaxel combination therapy in lung cancer

Oxis licenses PEG technology to Enzon

Cortecs announces phase II results for Pseudostat in chronic bronchitis

Endothelin antagonists disclosed by SKB

MS therapeutics from Lilly

Isodiagnostika, Glaxo Wellcome enter agreement for H. pylori breath test

NeoRx and Janssen enter agreement for Avicidin

Zomig approved in Germany, Denmark and Finland

Alteon receives U.S. patent for AGE cross-link breakers

Patent allowances granted to Genelabs for DNA-binding technology

NIH research grant goes to Diatide for arterial thrombosis therapy

Forest: Fiscal Q1 highlights

Gilead: Q2 1997 highlights

Atrix: Q2 1997 highlights

NABI: Q2 1997 highlights

NPS Pharmaceuticals: Q2 1997 highlights

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ASH 2025: New blood cancer therapies trump chemo, older drugs
BioWorld
Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...